[go: up one dir, main page]

MX2013008162A - Inhibidores de pirimidina y topoisomerasa iv. - Google Patents

Inhibidores de pirimidina y topoisomerasa iv.

Info

Publication number
MX2013008162A
MX2013008162A MX2013008162A MX2013008162A MX2013008162A MX 2013008162 A MX2013008162 A MX 2013008162A MX 2013008162 A MX2013008162 A MX 2013008162A MX 2013008162 A MX2013008162 A MX 2013008162A MX 2013008162 A MX2013008162 A MX 2013008162A
Authority
MX
Mexico
Prior art keywords
gyrase
topoisomerase
inhibitors
compounds
formula
Prior art date
Application number
MX2013008162A
Other languages
English (en)
Other versions
MX339455B (es
Inventor
Anne-Laure Grillot
Emanuele Perola
Paul S Charifson
Arnaud Le Tiran
Youssef Laafiret Bennani
Hardwin O'dowd
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2013008162A publication Critical patent/MX2013008162A/es
Publication of MX339455B publication Critical patent/MX339455B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo en donde X y R son como se definen en este documento. Los compuestos de la fórmula (I) son útiles como inhibidores de girasa y/o topoisomerasa IV para tratar infecciones bacterianas. Los compuestos de la fórmula (I) poseen ya sea un amplio intervalo de actividad anti-bacteriana y propiedades toxicológicas ventajosas o son profármacos de compuestos que tienen la actividad.
MX2013008162A 2011-01-14 2012-01-13 Inhibidores de pirimidina y topoisomerasa iv. MX339455B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161432965P 2011-01-14 2011-01-14
US201161499134P 2011-06-20 2011-06-20
US201161515249P 2011-08-04 2011-08-04
US201161515174P 2011-08-04 2011-08-04
PCT/US2012/021270 WO2012097269A1 (en) 2011-01-14 2012-01-13 Pyrimidine gyrase and topoisomerase iv inhibitors

Publications (2)

Publication Number Publication Date
MX2013008162A true MX2013008162A (es) 2013-08-27
MX339455B MX339455B (es) 2016-05-27

Family

ID=45567120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008162A MX339455B (es) 2011-01-14 2012-01-13 Inhibidores de pirimidina y topoisomerasa iv.

Country Status (18)

Country Link
US (2) US8481551B2 (es)
EP (1) EP2663557B1 (es)
JP (1) JP6085829B2 (es)
KR (1) KR101897952B1 (es)
CN (1) CN103443096B (es)
AR (1) AR084863A1 (es)
AU (1) AU2012205415B2 (es)
BR (1) BR112013017974B1 (es)
CA (1) CA2824516C (es)
CL (1) CL2013002025A1 (es)
ES (1) ES2545516T3 (es)
IL (1) IL227406A (es)
MX (1) MX339455B (es)
RU (1) RU2609259C2 (es)
SG (1) SG191946A1 (es)
TW (1) TWI546298B (es)
WO (1) WO2012097269A1 (es)
ZA (1) ZA201305233B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351555B (es) * 2011-01-14 2017-10-19 Spero Trinem Inc Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.
MX339455B (es) 2011-01-14 2016-05-27 Vertex Pharma Inhibidores de pirimidina y topoisomerasa iv.
CN103403000B (zh) * 2011-01-14 2017-05-31 斯派罗吹耐姆公司 固体形式的促旋酶抑制剂（r）‑1‑乙基‑3‑[6‑氟‑5‑[2‑（1‑羟基‑1‑甲基‑乙基）嘧啶‑5‑基]‑7‑（四氢呋喃‑2‑基）‑1氢‑苯并咪唑‑2‑基]脲
RU2619116C2 (ru) * 2011-01-14 2017-05-12 Сперо Тринем, Инк. Способ получения ингибиторов гиразы и топоизомеразы iv
US9125922B2 (en) * 2011-06-20 2015-09-08 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
AR093226A1 (es) * 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
KR20160115986A (ko) 2014-02-03 2016-10-06 스페로 자이레이스, 인크 폴리믹신을 포함하는 항균성 조합
BR112019000290B1 (pt) * 2016-07-07 2022-10-18 Cyclerion Therapeutics, Inc Prófármacos de fósforo dos estimuladores da sgc
RU2019133662A (ru) 2017-03-24 2021-04-26 Тайсо Фармасьютикал Ко., Лтд. Производное 2(1h)-хинолинона
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
CN109464471B (zh) * 2019-01-17 2023-09-19 广西医科大学 一种铜绿假单胞菌家兔脓胸脓絮状物生物膜模型建立方法
CN109464472B (zh) * 2019-01-17 2023-09-15 广西医科大学 一种铜绿假单胞菌家兔脓胸引流管生物膜模型建立方法
KR20240090712A (ko) * 2021-10-26 2024-06-21 스페로 테라퓨틱스, 인코퍼레이티드 Spr720의 인간 유효 용량 및 투여 스케줄
EP4622471A1 (en) * 2022-11-22 2025-10-01 University of Maryland, Baltimore Bovine colostrum-derived nutritional supplements and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
JPH09502987A (ja) 1993-09-22 1997-03-25 ゾーマ コーポレイション 殺菌性／浸透性が向上した（ｂｐｉ）タンパク質生成物および抗生物質の投与によるグラム陰性細菌感染の治療方法
ATE219684T1 (de) 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
EP1341769B1 (en) * 2000-12-15 2007-10-17 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
PL374315A1 (en) 2001-10-25 2005-10-03 Wisconsin Alumni Research Foundation Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
CN101538263A (zh) * 2002-06-13 2009-09-23 沃泰克斯药物股份有限公司 作为促旋酶和/或拓扑异构酶iv的抑制剂用于治疗细菌感染的2－脲基－6－杂芳基－3h－苯并咪唑－4－羧酸衍生物和相关化合物
AU2003245442B2 (en) 2002-06-13 2009-02-05 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CN101171247A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
AU2006311729A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
UA96964C2 (ru) 2006-12-04 2011-12-26 Астразенека Аб Соединения полициклической мочевины с антибактериальными свойствами
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
EP2321309A1 (en) 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
EA023350B1 (ru) 2009-10-16 2016-05-31 Мелинта Терапьютикс, Инк. Противомикробные соединения, способы их получения и применение
US9181234B2 (en) 2010-10-08 2015-11-10 Biota Europe Ltd. Antibacterial compounds
RU2619116C2 (ru) 2011-01-14 2017-05-12 Сперо Тринем, Инк. Способ получения ингибиторов гиразы и топоизомеразы iv
CN103403000B (zh) 2011-01-14 2017-05-31 斯派罗吹耐姆公司 固体形式的促旋酶抑制剂（r）‑1‑乙基‑3‑[6‑氟‑5‑[2‑（1‑羟基‑1‑甲基‑乙基）嘧啶‑5‑基]‑7‑（四氢呋喃‑2‑基）‑1氢‑苯并咪唑‑2‑基]脲
MX351555B (es) * 2011-01-14 2017-10-19 Spero Trinem Inc Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.
MX339455B (es) 2011-01-14 2016-05-27 Vertex Pharma Inhibidores de pirimidina y topoisomerasa iv.
US9125922B2 (en) * 2011-06-20 2015-09-08 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
US8906902B2 (en) 2012-03-22 2014-12-09 Biota Europe Limited Antibacterial compounds
AR093226A1 (es) * 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
US9572809B2 (en) * 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases

Also Published As

Publication number Publication date
KR20140037031A (ko) 2014-03-26
WO2012097269A1 (en) 2012-07-19
US20120184512A1 (en) 2012-07-19
RU2013137750A (ru) 2015-02-20
RU2609259C2 (ru) 2017-01-31
BR112013017974B1 (pt) 2021-05-25
TW201309677A (zh) 2013-03-01
CN103443096B (zh) 2016-06-29
US8481551B2 (en) 2013-07-09
US8969359B2 (en) 2015-03-03
MX339455B (es) 2016-05-27
AU2012205415A1 (en) 2013-08-01
CA2824516C (en) 2019-02-26
BR112013017974A2 (pt) 2018-05-02
NZ612961A (en) 2015-10-30
IL227406A0 (en) 2013-09-30
EP2663557B1 (en) 2015-05-27
ZA201305233B (en) 2014-11-26
CL2013002025A1 (es) 2013-12-27
TWI546298B (zh) 2016-08-21
JP6085829B2 (ja) 2017-03-01
EP2663557A1 (en) 2013-11-20
ES2545516T3 (es) 2015-09-11
AR084863A1 (es) 2013-07-10
JP2014503557A (ja) 2014-02-13
AU2012205415B2 (en) 2017-02-02
CN103443096A (zh) 2013-12-11
IL227406A (en) 2017-02-28
KR101897952B1 (ko) 2018-09-12
SG191946A1 (en) 2013-08-30
US20130289002A1 (en) 2013-10-31
CA2824516A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
MX2013008162A (es) Inhibidores de pirimidina y topoisomerasa iv.
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
IN2014CN04558A (es)
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
PH12012501650B1 (en) Heterocyclic compound
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
TN2011000400A1 (en) Inhibitors of beta-secretase
AU2012236166A8 (en) Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
MY170823A (en) Protein kinase inhibitors
MY172924A (en) Neprilysin inhibitors
PH12013501240A1 (en) Neprilysin inhibitors
SG191175A1 (en) Neprilysin inhibitors
IN2014CN04449A (es)
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2013008164A (es) Proceso para hacer inhibidores de girasa y topoisomerasa iv.
MX360856B (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
AU2012225365A8 (en) Peptide deformylase inhibitors
JO3723B1 (ar) مركبات دائرية مغايرة
HK1193097A (en) Macrocyclic compounds as alk, fak and jak2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration